Novartis Expects Further Profit, Growth After Key Drugs Boost Sales
Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...
Novartis Pharma AG: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Novartis Q4 Profit Down, Core EPS Beat Market; Lifts Dividend; Sees Growth In FY25
Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...
manilatimes27m
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income ...
Novartis beats consensus on Q4 earnings
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues. Fourth-quarter net income, adjusted for special items, rose 26% to $3.93 billion, the ...
Bluewin39m
Pharma Novartis grows significantly in the final quarter
Novartis increased sales by 15 percent to USD 13.2 billion in the fourth quarter of 2024. Profit rose by 7 percent to USD 2.8 ...